Results from recent trials have found that insulin degludec could reduce the risk of hypoglycaemia (when blood sugar levels are too low) - a common complication for people with diabetes.
Researchers found that people with both type 1 and type 2 diabetes had much lower rates of hypoglycaemia, or hypos, when taking Tresiba (insulin degludec), a once-daily basal insulin, when compared to people treated with insulin glargine U100.
It is estimated that on average, people with type 1 diabetes experience two episodes of hypoglycaemia per week and for people with type 2 diabetes, at least one episode per fortnight, with almost half of all types of hypos happening during the night.
People with diabetes could have less hypos when taking the new daily insulin treatment
Hypos can range from mild to severe and can greatly impact quality of life, affecting people’s sleep patterns, their relationships and their ability to work.
Dr Simon Heller, Professor of Clinical Diabetes at Sheffield University said: “Hypoglycaemia is a common concern for people with diabetes I see treated with insulin, particularly night-time episodes that are harder to detect and manage. The [study] results add important new evidence to the overall body of data supporting the use of insulin degludec for people living with type 1 or type 2 diabetes who experience problematic hypoglycaemia – and provide additional clinical approaches in this important group of patients.”
The results from the trials were presented at the 76th annual Scientific Sessions of the American Diabetes Association (ADA), held recently in New Orleans, USA.
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of